Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Which painkiller dose works best after kidney stone surgery?

NCT ID NCT07653230

Symptom relief Sponsor: Ankara Education and Research Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looked at two different strengths of the numbing medicine bupivacaine used in a nerve block for pain after kidney stone surgery. Sixty adults having the surgery received either a 0.25% or 0.375% concentration. Researchers measured their pain levels, how much extra pain medicine they needed, and changes in blood inflammation markers. The goal was to see if one concentration provides better pain relief.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
bupivacaine
What this could lead to
If successful, this could help doctors choose the best dose of bupivacaine for pain relief after kidney stone surgery, potentially reducing pain and opioid use.
What could go wrong
This is a small, completed study with only 60 participants. The results may not apply to all patients, and the two concentrations may show little difference in pain control.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

60 people

The number who actually took part.

Started

Jul 2024

Finished

Mar 2025

Lead sponsor

A government agency

The lead sponsor is a government body.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study population consisted of adult patients undergoing elective percutaneous nephrolithotomy (PNL) for renal stone disease at a single tertiary care center between July 2024 and March 2025. Eligible participants were 18-70 years of age, classified as American Society of Anesthesiologists (ASA) physical status I-III, and received ultrasound-guided thoracic erector spinae plane block (ESPB) as part of perioperative analgesic management. A total of 60 participants were included and prospectively followed throughout the postoperative period.

Ages

18 to 70 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Age between 18 and 70 years. * Scheduled to undergo elective percutaneous nephrolithotomy (PNL). * American Society of Anesthesiologists (ASA) physical status I-III. * Received ultrasound-guided thoracic erector spinae plane block (ESPB) before surgery. * Willing and able to provide written informed consent. Exclusion Criteria: * Inability to assess pain using the Visual Analog Scale (VAS). * Advanced cardiovascular disease. * Coagulopathy or bleeding disorders. * Opioid use disorder. * Body mass index (BMI) ≥ 40 kg/m². * Infection at the planned injection site. * Known allergy or hypersensitivity to bupivacaine, other local anesthetics, or study-related medications. * Withdrawal of consent during the study period.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Nephrolithiasis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Nephrolithiasis Percutaneous nephrolithotomy (PNL)

Contacts and locations

Locations

  • Ankara Training and Research Hospital

    Ankara, Mamak, 06420, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.